tbuckley/cabot-search huggingface dataset:
AB0165 PECULIARITIES OF BRUCELLIAN OSTEOARTICULAR INFECTIONS
Authors: A. Saad, K. Baccouche, R. Fakhfakh, C. Daldoul, D. Khalifa, H. Hachfi, N. El Amri, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Brucellosis is one of the most widespread zoonoses transmitted by animals in endemic areas. It is responsible for a range of clinical manifestations. The most frequent complication of brucellosis is osteoarticular involvement, with 10% to 85% of patients affected. <h3>Objectives:</h3> Characterize Osteoarticular Brucellosis in patients followed in the rheumatology department. <h3>Methods:</h3> Retrospective study that included patients followed in rheumatology in whom a Brucella osteoarthritis infection was confirmed. Socio-demographic, clinical, biological and radiological characteristics were collected. <h3>Results:</h3> We collected 34 cases, 21 (70.1%) men and 13 (38,24%) women. The mean age was 49 years [17-77]. the main symptoms were low back pain, lumbosciatic pain, back pain, neck pain, buttocks pain and knee pain in respectively 29.41%, 20.59%, 14.71%, 14.71%, 14.71% and 5.88% of cases. Fever and night sweats were associated in 71.9% of cases. Spondylodiscitis was the most frequent clinical form and represented 26 cases (76.47%) followed by sacroiliitis (6 cases, 17.65%). An osteoarthritis of the knee was reported in two cases. CRP level was elevated in 52% of patients. Brucella serology was positive in 97% of cases. Imaging confirmed osteoarticular damage in all cases, associated with epiduritis in 8 cases (23.53%) and a soft tissue abscess in 9 cases (26.47%).. No neurological complications were reported.All patients had received doxycycline and rifampicin associated with levofloxacin in 2 cases and corticosteroid therapy in one case. The evolution of the disease was favorable in 94.12% of cases and relapses was reported in 2 (5.88%) cases. <h3>Conclusion:</h3> Brucella spondylodiscitis was the most common clinical form of osteoarticular brucellosis. Early diagnosis helps limit complications and after-effects. Primary prevention by controlling animal brucellosis is essential. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1479-HPR TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY
Authors: E. De Lorenzis, G. Natalello, F. Cacciapaglia, R. De Angelis, E. Cipolletta, M. A. D’agostino, V. Codullo, G. De Luca, D. Giuggioli, F. Ingegnoli, V. Riccieri, C. Ferri, M. Matucci-Cerinic, S. L. Bosello
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Commuting poses a considerable burden and costs for patients with rare rheumatic diseases such as systemic sclerosis (SSc), who require care from tertiary medical centres. In a universal healthcare system, the selection of healthcare services is possibly influenced by geographical distribution, referral networks from primary care, and patient preferences. <h3>Objectives:</h3> This study aims to evaluate whether longer commuting distances are associated with clinical variables and differences in medication access among Italian SSc patients receiving follow-up care at tertiary centres. <h3>Methods:</h3> The driving distance from the city of residence to the care centre was calculated using the Google Maps Distance Matrix API for anonymized patients with SSc from the Systemic Sclerosis Progression INvestiGation (SPRING) Italian registry. This distance was then correlated with clinical and drug history in an ordinal logistic regression analysis. <h3>Results:</h3> The characteristics of 1,782 patients were obtained from 38 centres across the country (Figure 1 and Table 1): 74.2% were categorized as short-distance commuters (traveling less than 100 km), 20.1% as intermediate-distance commuters (traveling 100-500 km), and 5.6% as long-distance commuters (traveling more than 500 km). Notably, 24.6% of the patients received care outside their residential administrative region. Patients with interstitial lung disease (ILD), pulmonary arterial hypertension, lower Forced Vital Capacity (FVC), reduced Diffusion Capacity for Carbon Monoxide (DLCO), anti-Scl70 positivity, and anti-centromere negativity had higher probability of traveling longer distances. Similarly, access to multiple immunosuppressants (cyclophosphamide, azathioprine, methotrexate, tocilizumab) and vasoactive/vasodilator drugs (Endothelin Receptor Antagonists (ERA), Phosphodiesterase Type 5 Inhibitors (PDE5i), iloprost) was associated with increased probability of long travel distances (Table 1). No significant differences were correlated to demographics or comorbidity burden. <h3>Conclusion:</h3> SSc patients with pulmonary complications are more likely to undertake longer commuting distances and have a higher likelihood of receiving advanced treatments. Public health strategies should aim to enhance accessibility to specialized care and advanced therapies for these patients, recognizing the impact of travel burden on healthcare access. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1498-HPR ANXIETY AND DEPRESSION RISK AND ITS ASSOCIATION TO DISEASE ACTIVITY AND FATIGUE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: D. P. Flores-Gutierrez, G. Serna-Peña, L. F. Vega-Sevilla, M. E. Corral-Trujillo, M. F. Ortiz-Nuño, G. A. Madrid-Lopez, J. A. Cardenas-de la Garza, M. A. Villarreal-Alarcon, I. D. J. Hernandez-Galarza, D. A. Galarza-Delgado
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic lupus erythematosus (SLE) severely impacts the quality of life and increases the risk of mental health disorders. The prevalence of depression and anxiety in patients with SLE ranges from 2.1-78.6% and 2.9-84.9%, respectively. Some studies have reported a link between disease activity and the risk of depression or anxiety, while others have found no association between them. <h3>Objectives:</h3> To evaluate the relationship between disease activity and fatigue with the risk of anxiety and depression in patients with SLE. <h3>Methods:</h3> We performed a cross-sectional study in a university hospital. We included patients over 18 years old who fulfilled the EULAR/ACR 2019 criteria for SLE with at least 2 visits in the last year. From March to November 2023 patients were screened for depression and anxiety risk with the Hospital Anxiety and Depression Scale (HADS) and for fatigue with Functional Assessment of Chronic Illness Therapy Scale (FACIT) where higher scores indicate lower auto-perceived fatigue. A HADS score of 0 was classified as no risk, from 1-7 points as low risk, 8-10 as intermediate risk, and ≥11 as high risk. The disease activity was measured with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). <h3>Results:</h3> We included 84 patients of which 96.43% were women with a mean age of 38 ± 13.50 and a mean disease duration of 8.56 ± 8.09 years. Most of the patients did not present comorbidities, and only 34.5% had gone through menopause. Mean SLEDAI score was 1.44 ± 2.52. More than half had an SLEDAI score of 0 (52.38%) and 47.62% had a score of ≥1. Overall, 48.81% had a risk for anxiety, and 28.57% had a risk for depression. Table 1 describes the group characteristics of patients according to SLEDAI scores. There was a moderate negative correlation between fatigue and risk of anxiety (rho= -0.576, p= &lt;0.0001). We did not find a correlation between disease activity and anxiety or depression risk. <h3>Conclusion:</h3> In our cohort, almost half of the patients had a risk for anxiety and close to a quarter risk for depression. Lower FACIT scores correlated to a higher risk of anxiety. We did not find a correlation between disease activity and the risk of depression or anxiety. Regular mental health screening can be a valuable opportunity for patients to get timely psychological attention and improve their quality of life. <h3>REFERENCES:</h3> <b>NIL.</b> Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), Hospital Anxiety and Depression Scale (HADS). <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0179 IL 33 AND SECUKINUMAB, A LINK IN RHEUMATIC-RELATED GUT ALTERATION
Authors: F. Meyer, H. Martin, P. Totoson, D. Wendling, C. Demougeot, C. Prati, F. Verhoeven
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Subclinical gut inflammation, intestinal permeability and bacterial translocation are well described in inflammatory rheumatic diseases. While IL-17A is involved in the pathophysiology of both arthritis and inflammatory bowel diseases, the role of this cytokine in intestinal alterations related to rheumatic diseases has never been explored [1]. <h3>Objectives:</h3> Investigating the intestinal effects of an anti-IL-17A therapy (secukinumab) administered during the preclinical phase of adjuvant-induced arthritis (AIA) in rats, a model already known to present early intestinal alterations [2]. <h3>Methods:</h3> AIA was induced by injection of <i>Mycobacterium butyricum</i> in Freund's incomplete adjuvant at the base of the tail in male Lewis rats (day 0). AIA rats were treated, or not, with secukinumab (20mg/kg/3days, i.p.) from day 0 to day 4 (pre-clinical phase) or to day 11 (arthritis onset). Body weights and arthritis scores were monitored daily. Intestinal inflammation was assessed by measuring mRNA expression of proinflammatory cytokines (RT-qPCR). Intestinal permeability and integrity were evaluated by the measure of plasma zonulin and iFABP levels (ELISA). TLR4 mobilization was estimated by serum sCD14 levels (ELISA). <h3>Results:</h3> As compared to untreated AIA, secukinumab did not change body weights and arthritis scores whatever the treatment duration. Plasma levels of zonulin and iFABP were unchanged by the treatment, both at day 4 and day 11. By contrast, higher serum levels of sCD14 were measured at days 4 and 11 under secukinumab treatment. Likewise, the treatment with secukinumab increased ileal mRNA expression of IL-33 but not IL-1β, IL-8, IL-17A, IL-23p19 and TNFα at days 4 and 11. <h3>Conclusion:</h3> Blockade of IL-17A, during the preclinical phase of the AIA model, did not change intestinal permeability and epithelial damage but increased potential TLR4 mobilization and IL-33 gene expression. These data suggest a specific role of IL-17A in rheumatic-related intestinal changes and encourage further exploration of the IL-17A/IL-33 pathway in this setting. <h3>REFERENCES:</h3> [1] Meyer F. et al. Autoimmun. Rev.2023;22(6):103331. [2] Hecquet S. et al. Arthritis Res. Ther.2023;25(1):95. <h3>Acknowledgements:</h3> For the financial support of French Society for Rheumatology (SFR). <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0176 SERUM CALPROTECTIN LEVELS MEASURED BY CHEMILUMINESCENCE IMMUNOASSAY AS AN INFLAMMATION BIOMARKER IN RHEUMATOID AND PSORIATIC ARTHRITIS IN RELATION TO OTHER BIOCHEMICAL AND DISEASE ACTIVITY PARAMETERS
Authors: C. Dominguez, D. Ruiz-Montesino, I. Olivas, C. Gonzalez, J. J. Pérez Venegas
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Several studies reported correlation among ELISA serum calprotectin (cCLP) levels, biochemical inflammatory parameters and disease activity in rheumatoid (RA) and psoriatic (PsA) arthritis. Recently, a chemiluminescence immunoassay (CLIA) for fecal CLP was successfully adapted to measure cCLP. <h3>Objectives:</h3> To assess CLIA cCLP levels as inflammatory and activity marker and to study its relation with other biochemical parameters in RA and PsA patients. <h3>Methods:</h3> Eighty-eight subjects were studied: 1) RA patients treated with disease modifying drugs (DMARD) with low or no activity by common clinical indexes (rRA=11), 2) RA patients candidate to start treatment with biological DMARD (aRA=23), 3) PsA patients treated with DMARD with low or no activity by common clinical indexes (rPsA=11), 4) PsA patients candidate to start treatment with biological DMARD (aPsA=10) and 5) non-disease controls (n=33). Disease activity scores were DAS28 (RA) and DAPSA (PsA). Different serum and plasma inflammatory parameters were also analyzed. Statistical GraphPadv7.0S and SPSSv26 programs were used. <h3>Results:</h3> cCLP concentrations were significantly increased in aRA and aPsA vs controls, as well as in aRA vs rRA. cCLP levels were directly correlated with other biochemical inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein, Serum Amyloid-A), and DAS28 activity index in RA groups. Area under curve (AUC) of 0.66 (p=0.047) and 0.92 (p&lt;0.0001) were obtained for cCLP to classify active/remission RA and PsA patients, using a ROC analysis with DAS28 and DAPSA indexes, respectively. <h3>Conclusion:</h3> In RA and PsA patients, cCLP is a suitable inflammation biomarker, well correlated with other biochemical inflammatory parameters and the disease activity degree. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0185 CLINICALLY SUSPECT ARTHRALGIA AND RHEUMATOID ARTHRITIS: PATIENTS’ PERCEPTIONS OF ILLNESS
Authors: S. J. H. Khidir, P. H. P. De Jong, A. Willemze, A. H. M. Van der Helm – van Mil, E. Van Mulligen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Clinically suspect arthralgia (CSA) is an at-risk stage of rheumatoid arthritis (RA), in which patients experience symptoms and physical limitations. Perceptions of CSA-patients have remained largely unknown. <h3>Objectives:</h3> Therefore, we aimed to map perceptions of CSA-patients and compare them to RA-patients. Additionally, we studied changes in perceptions in CSA over time. <h3>Methods:</h3> 399 consecutive CSA-patients from the Leiden and Rotterdam CSA-cohorts and 100 recently diagnosed RA-patients from the Leiden Early Arthritis Clinic were included. Patients' illness perceptions (IP) were assessed using the Brief Illness Perception Questionnaire (BIPQ), consisting of 8 questions (scale 0-10; higher score indicating more negative IP) covering cognitive, emotional and comprehensibility domains, and one open question on causes of disease. IP were measured at baseline in both populations and during 2 years follow-up in the CSA-cohorts. <h3>Results:</h3> Total BIPQ-scores were comparable at CSA-presentation and RA-diagnosis (40±11 and 40±10; range 0-80; Figure 1A). Comparing dimensions separately revealed that CSA-patients were less worried on physical complaints compared to RA-patients. However, CSA-patients were more negative about expected effect from treatment on symptoms (Figure 1B). IP over time in CSA improved in patients without development of clinical arthritis (38±11 to 34±14; p=0.005) but remained similar in CSA-patients who progressed to arthritis/RA (mean 40 at both timepoints). CSA-patients mainly reported physical strain and heredity as perceived causes of their complaints. <h3>Conclusion:</h3> Although CSA-patients have not developed clinical arthritis, illness perceptions at CSA-presentation and RA-diagnosis are equally severe. Knowledge on worries and expectations may contribute to improving patient-contact and care in patients at risk of RA. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0141 NEUROPATHIC AND NOCIPLASTIC PAIN ARE COMMON IN ADULT CHRONIC NONBACTERIAL OSTEITIS (CNO)
Authors: E. Winter, A. Leerling, M. Niesters, M. Flendrie, M. Tel, N. Appelman-Dijkstra, O. Dekkers
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Chronic nonbacterial osteitis (CNO) is a rare bone disease that has historically been labelled as synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO)-syndrome due to its wider spectrum of inflammatory features. CNO is characterized by sterile bone inflammation causing bone pain. However, other mechanisms beyond nociceptive inflammatory pain may be involved in patients' pain experience. <h3>Objectives:</h3> We investigate the prevalence of neuropathic and nociplastic pain profiles in adult CNO and assess their association with clinical characteristics and treatment outcomes. <h3>Methods:</h3> Survey study among the Dutch adult CNO cohort. Patients were invited to participate in surveys about pain profiles, including PAIN-detect for neuropathic pain, Central Sensitization Inventory (CSI), Fibromyalgia Rapid Screening Tool (FiRST), and ACTTION-APS Pain Taxonomy (AAPT) scoring for nociplastic pain and symptoms consistent with fibromyalgia. Clinical characteristics and CNO-related pain scores assessed by Brief Pain Inventory were compared between patients with nociceptive pain exclusively and those with nociceptive pain plus neuropathic and/or nociplastic pain (mixed pain profile). <h3>Results:</h3> 80 patients participated in the surveys (response rate 44%). 31% (95% CI 21-41) of patients classified as "likely (&gt;90% probability)" having neuropathic pain according to PAIN-detect. 53% (95% CI 41-64) of patients displayed degrees of sensitization consistent with a nociplastic pain profile. 61% (50-72) screened positive for fibromyalgia on FiRST and 14% (7-23) of patients fulfilled the AAPT criteria for fibromyalgia. The presence of neuropathic and/or nociplastic pain (mixed pain profile) was associated with longer diagnostic delay (mean difference 2.8 years, 95% CI 0.4-5.2, p=0.023), lower educational level (72% versus 20%, p&lt;0.001), and opioid use for CNO-related symptoms (37% versus 13%, p=0.036). Despite comparable disease duration and extent, patients with a mixed pain profile reported significantly higher CNO-related bone pain scores. <h3>Conclusion:</h3> This study demonstrates the frequent coexistence of neuropathic and nociplastic pain alongside nociceptive inflammatory bone pain in adult CNO patients. Disease burden in CNO may extend beyond just inflammatory activity, highlighting the need for a multifaceted management approach. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0146 PAIN ASSESSMENT IN HOSPITALIZED OLDER ADULTS: COMPARISON OF TWO PAIN SCALES: THE VERBAL RATING SCALE (VRS) AND THE VISUAL ANALOG SCALE (VAS)
Authors: R. Grassa, B. Njah, N. Ben Chekaya, N. Hafdhouni, M. Jguirim, S. Zrour, M. Touzi, N. Bergaoui, I. Bejia
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Positive diagnosis and assessment of pain are crucial in the elderly, a population where pain is often underestimated. The literature suggests various tools commonly used in clinical practice, including the Visual Analog Scale (VAS) and the Verbal Rating Scale (VRS). <h3>Objectives:</h3> This study aimed to investigate the correlation and degree of agreement between VRS and VAS in pain assessment among hospitalized elderly subjects and establish potential recommendations for interchangeable use of the two scales. <h3>Methods:</h3> This was a monocentric, cross-sectional, diagnostic, and comparative study conducted in December 2019 at various departments of Fattouma Bourguiba Hospital in Monastir over a period of seven consecutive days. <h3>Results:</h3> Forty-three patients were included, of whom 62.8% were male. All these patients sought consultation for a painful condition. A surgical cause was found in 83.7% of cases, followed by medical causes in 16.3% of cases. Upon admission, the mean VAS score was 58.6 ± 17.8. Forty-two percent of patients had severe pain according to VAS. In contrast, 67.4% of patients rated their pain as severe according to VRS (mean 2.63 ± 0.69). The correlation study between VRS and VAS measurements at admission revealed a strong positive linear correlation (n=43, r=0.805, p &lt;0.001). Additionally, the correlation remained strong after analgesic treatment (n=43, r=0.822, p &lt;0.001). The degree of agreement assessed by the Kappa test found good (measure of agreement of 0.876 with p &lt;0.001) to moderate (measure of agreement between 0.4 and 0.6) concordance between VAS and VRS. Regarding preference, VRS was preferred by more than half of the patients (72% of cases), mainly due to its ease of understanding. <h3>Conclusion:</h3> Based on these tests and results, it can be concluded that the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) are strongly correlated and concordant, allowing for interchangeable use. Indeed, these two measurement scales have proven to be reliable and effective, demonstrating practical equivalence in the elderly and offering similar performance in terms of effectiveness. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1484 PERFORMANCE OF THE NEW PREVENT CARDIOVASCULAR RISK CALCULATOR TO DETECT HEART FAILURE IN PATIENTS WITH RHEUMATIC DISEASES
Authors: V. Gonzalez-Gonzalez, J. R. Azpiri-Lopez, D. A. Galarza-Delgado, I. J. Colunga-Pedraza, J. A. Cardenas-de la Garza, R. I. Arvizu-Rivera, N. Guajardo-Jauregui, M. F. Elizondo-Benitez, A. L. Guajardo-Aldaco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatic diseases have a higher risk of heart failure compared to the non-rheumatic population. Several cardiovascular risk (CVR) algorithms are used to predict cardiovascular outcomes, but none of them provide heart failure risk among this population. The predicting risk of cardiovascular disease EVENTs (PREVENT) calculator uniquely estimates atherosclerotic disease and heart failure risks, offering a cost-effective approach to population health. <h3>Objectives:</h3> To evaluate the performance of PREVENT in detecting heart failure in patients with rheumatic diseases. <h3>Methods:</h3> A cross-sectional, descriptive study of patients aged 30-79 years who met the ACR/EULAR 2010 classification criteria for RA or the ACR/EULAR 2019 classification criteria for the diagnosis of SLE. Patients with previous cardiovascular disease (myocardial infarction, stroke, or peripheral artery disease) were excluded. Prediction of heart failure (HF) risk using the PREVENT algorithm. Transthoracic echocardiography was performed by one certified cardiologist blinded to clinical information. HF was defined according to the presence of diastolic (DD) and systolic dysfunction (SD) based on the guidelines of the American Society of Echocardiography. A ROC curve analysis was performed to evaluate the performance of the PREVENT algorithm for detecting HF in each rheumatic disease. The Youden index was calculated to select the optimum sensitivity, specificity, and negative and positive predictive values. A value of <i>p</i>≤0.05 was considered statistically significant. <h3>Results:</h3> A total of 198 patients with rheumatic disease were included, divided into two groups, 156 RA patients, and 42 SLE patients. The prevalence of HF was 58.08%. Demographic characteristics and results are shown in Table 1 and Figure 1. <h3>Conclusion:</h3> In our study, the PREVENT algorithm performed poorly in detecting heart failure in RA patients. In SLE, the algorithm does not seem to work. Further prospective studies with larger numbers of patients are needed to evaluate the prognostic utility of the new cardiovascular algorithm, PREVENT, for predicting heart failure outcomes in patients with rheumatic diseases. <h3>REFERENCES:</h3> [1] Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation 2023;148(24):1982-2004. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>